These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21395547)

  • 1. Impact of renin-angiotensin system in hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Fukui H
    Curr Cancer Drug Targets; 2011 May; 11(4):431-41. PubMed ID: 21395547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
    Yoshiji H; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Tsujimoto T; Uemura M; Fukui H
    Curr Med Chem; 2007; 14(26):2749-54. PubMed ID: 18045121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress.
    Kaji K; Yoshiji H; Ikenaka Y; Noguchi R; Aihara Y; Shirai Y; Douhara A; Fukui H
    Curr Med Chem; 2012; 19(12):1889-98. PubMed ID: 22376037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
    Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Yamazaki M; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
    Oncol Rep; 2011 Dec; 26(6):1547-53. PubMed ID: 21874260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
    Barone M; Viggiani MT; Losurdo G; Principi M; Leo AD
    World J Gastroenterol; 2019 May; 25(20):2524-2538. PubMed ID: 31171895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
    Yoshiji H; Noguchi R; Kaji K; Ikenaka Y; Shirai Y; Namisaki T; Kitade M; Tsujimoto T; Kawaratani H; Fukui H
    J Gastroenterol; 2010 Apr; 45(4):443-50. PubMed ID: 19941011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Akahane T; Asada K; Tsujimoto T; Uemura M; Fukui H
    Oncol Rep; 2006 Jan; 15(1):155-9. PubMed ID: 16328049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy.
    Yoshiji H; Kuriyama S; Noguchi R; Fukui H
    Curr Cancer Drug Targets; 2004 Nov; 4(7):555-67. PubMed ID: 15578913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
    J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
    J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
    Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
    Yoshiji H; Noguchi R; Namisaki T; Moriya K; Kitade M; Aihara Y; Douhara A; Yamao J; Fujimoto M; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Uejima M; Uemura M; Fukui H
    Oncol Rep; 2013 Aug; 30(2):545-52. PubMed ID: 23708326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.
    Nishimura N; Kaji K; Kitade M; Aihara Y; Sato S; Seki K; Sawada Y; Takaya H; Okura Y; Kawaratani H; Moriya K; Namisaki T; Mitoro A; Yoshiji H
    BMC Cancer; 2018 Nov; 18(1):1164. PubMed ID: 30477453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y
    Oncol Rep; 2005 Mar; 13(3):491-5. PubMed ID: 15706423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
    Saber S; Mahmoud AAA; Goda R; Helal NS; El-Ahwany E; Abdelghany RH
    Toxicol Lett; 2018 Oct; 295():32-40. PubMed ID: 29859236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
    Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Nasr M; Selima E; Hamed O; Kazem A
    Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Yoshii J; Yanase K; Namisaki T; Yamazaki M; Tsujimoto T; Kawaratani H; Fukui H
    Hepatol Res; 2010 May; 40(5):540-9. PubMed ID: 20412330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.